EIF2A and neoplasm: The latest research shows that DHA inhibits tumor progress via blocking ROR1-induced STAT3-activation (Li J.-Y et al., 2022; Li et al., 2024b), inhibits angiogenesis via regulating VEGF and MMP-2/-9 (Rao et al., 2024), remodels tumor micro-environment and improves cancer immunotherapy through inhibiting cyclin-dependent kinases (Zhou et al., 2024), restores the immunogenicity and enhances the anticancer immunosurveillance of cisplatin by activating the PERK/eIF2α pathway (Li G et al., 2022).